CN102822169A - 取代的萘基-嘧啶化合物 - Google Patents
取代的萘基-嘧啶化合物 Download PDFInfo
- Publication number
- CN102822169A CN102822169A CN2010800649939A CN201080064993A CN102822169A CN 102822169 A CN102822169 A CN 102822169A CN 2010800649939 A CN2010800649939 A CN 2010800649939A CN 201080064993 A CN201080064993 A CN 201080064993A CN 102822169 A CN102822169 A CN 102822169A
- Authority
- CN
- China
- Prior art keywords
- substituted
- replace
- alkyl
- sec
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C(*)(C=C1)C=C2)(C1=C1)C2=C(C(C*)C*)C=C1C1=NC(N(*)C2=*C2)=*CC(*)=C1* Chemical compound CC(C(*)(C=C1)C=C2)(C1=C1)C2=C(C(C*)C*)C=C1C1=NC(N(*)C2=*C2)=*CC(*)=C1* 0.000 description 5
- UVOAUGYHOPLCAK-MKHIWHRVSA-N CC/C=C(\CC)/C[C@H](C)/C(/OC)=N\C(NCc1cc(OC)ccc1)=N Chemical compound CC/C=C(\CC)/C[C@H](C)/C(/OC)=N\C(NCc1cc(OC)ccc1)=N UVOAUGYHOPLCAK-MKHIWHRVSA-N 0.000 description 1
- RCZVSSDMFYMUPY-UHFFFAOYSA-N COc1cccc(CNc2nc(-c3cc(ccc(OC)c4)c4c(N4CCN(CCCN5CCCC5)CC4)c3)ccn2)c1 Chemical compound COc1cccc(CNc2nc(-c3cc(ccc(OC)c4)c4c(N4CCN(CCCN5CCCC5)CC4)c3)ccn2)c1 RCZVSSDMFYMUPY-UHFFFAOYSA-N 0.000 description 1
- LMLOMLTWRGLOLF-UHFFFAOYSA-N COc1cccc(CNc2nc(-c3cc(ccc(OC)c4)c4c(N4CCN(CCCN5CCCCC5)CC4)c3)ccn2)c1 Chemical compound COc1cccc(CNc2nc(-c3cc(ccc(OC)c4)c4c(N4CCN(CCCN5CCCCC5)CC4)c3)ccn2)c1 LMLOMLTWRGLOLF-UHFFFAOYSA-N 0.000 description 1
- LWEOFVINMVZGAS-UHFFFAOYSA-N OCCCN1CCNCC1 Chemical compound OCCCN1CCNCC1 LWEOFVINMVZGAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29091309P | 2009-12-30 | 2009-12-30 | |
US61/290,913 | 2009-12-30 | ||
PCT/US2010/062437 WO2011082268A2 (en) | 2009-12-30 | 2010-12-29 | Substituted naphthalenyl-pyrimidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102822169A true CN102822169A (zh) | 2012-12-12 |
Family
ID=44225054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800649939A Pending CN102822169A (zh) | 2009-12-30 | 2010-12-29 | 取代的萘基-嘧啶化合物 |
Country Status (10)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
WO2011103289A2 (en) * | 2010-02-17 | 2011-08-25 | Jasco Pharmaceuticals, LLC | Imidazole-2, 4-dione inhibitors of casein kinase 1 |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
WO2014086453A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
CN104193644B (zh) * | 2014-09-27 | 2015-12-02 | 张远强 | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 |
AU2016341109A1 (en) * | 2015-10-18 | 2018-06-07 | Onco Therapies Llc | Compositions and methods of regulating cancer related disorders and diseases |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TW201811795A (zh) | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基-吡咯并嘧啶酮化合物及其用途 |
WO2022147622A1 (en) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008060766A2 (en) * | 2006-10-02 | 2008-05-22 | Abbott Laboratories | Histamine h4 receptor ligands for use in pain treatment |
US20080287452A1 (en) * | 2007-05-16 | 2008-11-20 | Wyeth | Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
US20090048282A1 (en) * | 2007-08-14 | 2009-02-19 | Wyeth | Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
WO2009026319A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE834993C (de) | 1944-05-27 | 1952-03-27 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von 2, 6-Dioxy-4-aminopyrimidin-5-aminosulfonsaeure in Form ihrer Salze |
GB681712A (en) | 1949-09-14 | 1952-10-29 | Burroughs Wellcome Co | Improvements in or relating to therapeutically useful pyrimidine compounds |
US2691655A (en) | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
DE4025891A1 (de) | 1990-08-16 | 1992-02-20 | Bayer Ag | Pyrimidyl-substituierte acrylsaeureester |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
KR20040066296A (ko) | 2003-01-17 | 2004-07-27 | 주식회사 엘지생명과학 | 3-(2-아미노-4-피리미디닐)-2-나프톨 구조를 갖는사이클린 의존 키나아제 저해제 |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
US20070099938A1 (en) | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
KR20070084067A (ko) | 2004-10-13 | 2007-08-24 | 와이어쓰 | N-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
CA2637245A1 (en) | 2006-01-17 | 2007-07-26 | Signal Pharmaceuticals, Llc | Inhibitors of tnf.alpha., pde4 and b-raf, compositions thereof and methods of use therewith |
DE102006008880A1 (de) | 2006-02-27 | 2007-09-06 | Merck Patent Gmbh | Aminopyrimidinderivate |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
EP1903037A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
JP2010507698A (ja) | 2006-10-25 | 2010-03-11 | チバ ホールディング インコーポレーテッド | 熱安定性のカプセル化顔料 |
EA200970669A1 (ru) | 2007-02-06 | 2010-02-26 | Пфайзер Инк. | Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака |
US20100297009A1 (en) | 2007-03-13 | 2010-11-25 | Technion Research & Development Foundation Ltd. | Self-assembled polyhedral multimeric chemical structures |
CA2681516A1 (en) | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of janus kinases |
WO2008121570A1 (en) | 2007-03-29 | 2008-10-09 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
CN101679418A (zh) * | 2007-04-06 | 2010-03-24 | 诺瓦提斯公司 | 用作蛋白质激酶抑制剂的[2,6]萘啶类化合物 |
DE102007017656A1 (de) | 2007-04-12 | 2008-10-16 | Henkel Ag & Co. Kgaa | Biheteroaryl-Metallkomplexe als Bleichkatalysatoren |
RU2478099C2 (ru) | 2007-07-27 | 2013-03-27 | Актелион Фармасьютиклз Лтд | Производные 2-аза-бицикло[3.3.0]октана |
TW200904799A (en) | 2007-07-27 | 2009-02-01 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
-
2010
- 2010-12-29 CA CA2788450A patent/CA2788450A1/en not_active Abandoned
- 2010-12-29 CN CN2010800649939A patent/CN102822169A/zh active Pending
- 2010-12-29 KR KR1020127020146A patent/KR20130005263A/ko not_active Application Discontinuation
- 2010-12-29 EP EP10841700.7A patent/EP2519519A4/en not_active Withdrawn
- 2010-12-29 WO PCT/US2010/062437 patent/WO2011082268A2/en active Application Filing
- 2010-12-29 NZ NZ601508A patent/NZ601508A/xx not_active IP Right Cessation
- 2010-12-29 AU AU2010339531A patent/AU2010339531A1/en not_active Abandoned
- 2010-12-29 US US12/981,113 patent/US8173808B2/en active Active
- 2010-12-30 TW TW099146872A patent/TW201139410A/zh unknown
-
2012
- 2012-07-30 ZA ZA2012/05726A patent/ZA201205726B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008060766A2 (en) * | 2006-10-02 | 2008-05-22 | Abbott Laboratories | Histamine h4 receptor ligands for use in pain treatment |
US20080287452A1 (en) * | 2007-05-16 | 2008-11-20 | Wyeth | Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
US20090048282A1 (en) * | 2007-08-14 | 2009-02-19 | Wyeth | Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
WO2009026319A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
Non-Patent Citations (1)
Title |
---|
JEAN-MICHEL DELACOTTE,等: "Heterocycles with quinone function IX. Synthesis and cytotoxic activity of several 6-(4-pyrimidinyl)-1,4-naphthalenediones", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011082268A3 (en) | 2011-10-20 |
US8173808B2 (en) | 2012-05-08 |
WO2011082268A2 (en) | 2011-07-07 |
CA2788450A1 (en) | 2011-07-07 |
US20110166137A1 (en) | 2011-07-07 |
AU2010339531A1 (en) | 2012-08-23 |
NZ601508A (en) | 2013-07-26 |
KR20130005263A (ko) | 2013-01-15 |
TW201139410A (en) | 2011-11-16 |
ZA201205726B (en) | 2013-09-25 |
EP2519519A2 (en) | 2012-11-07 |
EP2519519A4 (en) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6837525B2 (ja) | 増殖性障害を処置するための組成物および方法 | |
JP6046710B2 (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物 | |
TWI529162B (zh) | 經芳基或雜芳基取代的苯化合物 | |
TWI461410B (zh) | 經取代之5,6-二氫-6-苯基苯並〔f〕異喹啉-2-胺化合物類 | |
US8563567B2 (en) | Substituted heterocyclic compounds | |
CN102892768A (zh) | 被取代的吡咯并氨基嘧啶化合物 | |
JP2017190337A (ja) | がんを処置するための組合せ治療 | |
CN102822169A (zh) | 取代的萘基-嘧啶化合物 | |
US8815854B2 (en) | Substituted imidazopyridinyl compounds | |
US8541407B2 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
CN102781940A (zh) | 取代的咪唑并吡啶基-氨基吡啶化合物 | |
TW201100428A (en) | Substituted indolo-piperidine compounds | |
TW201522337A (zh) | 經取代之三環吡唑並-嘧啶化合物類 | |
ES2664332T3 (es) | N-(3-fluorobencil)-2-(5-(4-morfolinofenil)piridin-2-il) acetamida como moduladores de la proteína tirosina quinasa | |
MX2013014433A (es) | Composiciones y metodos para modular una cinasa. | |
TWI525091B (zh) | 吡咯並喹啉基-吡咯啶-2,5-二酮組成物類及製備和使用彼等之方法 | |
US20100249120A1 (en) | Substituted pyrazolo-pyrrolo-pyridine-dione compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121212 |